• Assembly Biosciences outlined three Phase 2 starts across its portfolio in late 2026 to early 2027, with key data readouts in 2027-2028.
• ABI-6250 Phase 2 in hepatitis D targeted for 4Q 2026, with data expected in 4Q 2027.
• A separate ABI-6250 Phase 2 in primary biliary cholangitis or primary sclerosing cholangitis targeted for 1Q 2027, with data expected in 1H 2028.
• Gilead-selected HSV candidate GS-1179 is slated for Phase 2 in recurrent genital herpes in 4Q 2026 under the companies’ collaboration.
• Cash runway projected into 2029, supported by about $320.4 million cash at June 30, 2026, with a $75 million collaboration payment due in 4Q 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.